Peter Hodson Draxis Health Inc DAX-T BUY ON WEAKNESS Mar 02, 2004

Likes what the company is doing. Starting to develop their US relationships. Last quarterly results were excellent. On his watch list.

Peter Hodson

Unlock Rating

$6.100

Stock price when the opinion was issued

biotechnology pharmaceutical

It's the ideal tool to help you make quicker, more informed decisions for managing and tracking your investments.

Get Signals Create your Watchlist

You might be interested:

TOP PICK

Earnings revisions is up 13%. Year-over-year sales are up 29%. Earnings growth is up 107%.

TOP PICK

Forecasting 35/40% on manufacturing growth. Earnings are growing substantially from three cents to eight cents. Sales growth of 27%.

TOP PICK

Good technical pattern. Has been in a congestion area for quite awhile, went through a bit of a correction and has just broke out.

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : hello@stockchase.com.

Peter Hodson Draxis Health Inc DAX-T BUY ON WEAKNESS Mar 02, 2004

You might be interested:

Draxis Health Inc(DAX-T)

Draxis Health Inc(DAX-T)

Draxis Health Inc(DAX-T)

Latest Buy Signals

Today's Top Picks

Popular Articles

Latest Sell Signals

Most Recent Experts

Bruce Murray

The Panic-Proof Portfolio (Stockchase Research)

The Weekly Buzzing Stocks by Billy Kawasaki

Chris Blumas

Stockchase Insights